Robert Mennel
Texas Oncology(US)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Sarcoma Diagnosis and Treatment, Breast Cancer Treatment Studies, Vascular Tumors and Angiosarcomas, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer(2007)2,211 cited
- → 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*(2001)884 cited
- → Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline(2016)810 cited
- → Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers(1996)751 cited
- → Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735(2009)585 cited
- → Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer(2005)547 cited
- → Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer(2006)537 cited
- → Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial(2000)525 cited
- → Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline(2015)390 cited
- → Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update(2017)315 cited